Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00194714 | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab | completed | Phase 1 / Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04408118 | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC(ATRACTIB) | completed | Phase 2 | 100 | MedSIROTHER | 5 | Jun 4, 2024 | clinicaltrials |
| NCT00204490 | Soy Isoflavones and Breast Cancer Risk Reduction | completed | Phase 2 | 197 | The University of Texas Medical Branch, GalvestonOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04129216 | The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer | completed | Phase 2 | 30 | Johns Hopkins UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT01377324 | Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites | completed | Phase 2 | 16 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01988324 | AR and ER Imaging in Metastatic Breast Cancer | completed | Phase 2 | 24 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT00796978 | Trastuzumab in Treating Older Women With Early-Stage Breast Cancer | completed | Phase 2 | 56 | Cynthia Owusu, MDOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT03887130 | Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer | completed | Phase 2 | 152 | Pierre Fabre MedicamentINDUSTRY | 0 | Apr 30, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT02448420 | Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer(PATRICIA II) | completed | Phase 2 | 73 | SOLTI Breast Cancer Research GroupOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT03272477 | Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients(TP-II) | completed | Phase 2 | 257 | Palleos Healthcare GmbHINDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05850637 | Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer | completed | Phase 2 | 60 | Prevent Senior InstituteOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03703466 | A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer | completed | Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 5 | Apr 2, 2024 | clinicaltrials |
| NCT03007979 | Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer | completed | Phase 2 | 55 | Washington University School of MedicineOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02648477 | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | completed | Phase 2 | 30 | City of Hope Medical CenterOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05112536 | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer | completed | Phase 2 | 24 | G1 Therapeutics, Inc.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT00036868 | Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer | completed | Phase 2 | 90 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Mar 8, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT00096434 | Sorafenib in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03051659 | A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer | completed | Phase 2 | 90 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT03752723 | Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) | completed | Phase 1 / Phase 2 | 84 | Genexine, Inc.INDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT00618657 | Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | completed | Phase 2 | 127 | University of California, IrvineOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02954055 | MEtronomic TrEatment Option in Advanced bReast cAncer(METEORA-II) | completed | Phase 2 | 140 | ETOP IBCSG Partners FoundationNETWORK | 1 | Feb 26, 2024 | clinicaltrials |
| NCT00712881 | Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer | completed | Phase 2 | 126 | Cephalon, Inc.INDUSTRY | 6 | Feb 23, 2024 | clinicaltrials |
| NCT02971761 | Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 18 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03853707 | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03326102 | Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer(OPERA) | completed | Phase 2 | 72 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 2 | Feb 16, 2024 | clinicaltrials |
| NCT04240106 | Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)(LUZERN) | completed | Phase 2 | 14 | MedSIROTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT02456857 | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | completed | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT00482755 | Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | completed | Phase 2 | 4 | NCIC Clinical Trials GroupNETWORK | 1 | Feb 12, 2024 | clinicaltrials |
| NCT03878823 | Safety and Pharmacokinetics of ODM-209(STESIDES) | completed | Phase 1 / Phase 2 | 38 | Orion Corporation, Orion PharmaINDUSTRY | 3 | Feb 1, 2024 | clinicaltrials |
| NCT03306472 | A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer(PIONEER) | completed | Phase 2 | 198 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT00204477 | Soy Protein and Breast Cancer Risk Reduction | completed | Phase 2 | 321 | The University of Texas Medical Branch, GalvestonOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03312738 | A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor(BOLERO-5) | completed | Phase 2 | 159 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04596150 | Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer | completed | Phase 2 | 125 | CytomX TherapeuticsINDUSTRY | 3 | Jan 23, 2024 | clinicaltrials |
| NCT00494234 | Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer(ICEBERG 1) | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 8 | Jan 19, 2024 | clinicaltrials |
| NCT04805736 | Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer | completed | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04983238 | Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 | completed | Phase 1 / Phase 2 | 48 | Byondis B.V.INDUSTRY | 3 | Jan 5, 2024 | clinicaltrials |
| NCT03742986 | Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) | completed | Phase 2 | 8 | NYU Langone HealthOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT03052634 | A Study of RC48-ADC in Subjects With Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 112 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT02027818 | Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy | completed | Phase 2 | 20 | Jules Bordet InstituteOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT02834403 | L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients | completed | Phase 1 / Phase 2 | 37 | The Methodist Hospital Research InstituteOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03831711 | 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 5 | Andrei IagaruOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02297698 | Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients(HER3+) | completed | Phase 2 | 100 | Cancer Insight, LLCINDUSTRY | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | completed | Phase 2 | 27 | Joel NealOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT01387295 | Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease | completed | Phase 2 | 38 | Dorte NielsenOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT02636582 | Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04150731 | 16α-18F-fluor-17β-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer | completed | Phase 1 / Phase 2 | 8 | University of AarhusOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04222790 | A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity | completed | Phase 2 | 159 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 4, 2023 | clinicaltrials |
| NCT00006256 | Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer | completed | Phase 2 | 44 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 30, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2024source: clinicaltrials